GlycoMimetics today announced that Chief Executive Officer Rachel King will provide a company overview at two healthcare investor conferences next week.
GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that Chief Executive Officer Rachel King will provide a company overview at two healthcare investor conferences next week, as follows:
STIFEL 2016 HEALTHCARE CONFERENCE
WHEN: NOVEMBER 15,
2016 AT 4:30 PM ET
WHERE: NEW YORK, NY, USA
JEFFERIES 2016 LONDON HEALTHCARE CONFERENCE
17, 2016 AT 1:20 PM GMT
WHERE: LONDON, UK
To access the live webcast and subsequent archived recordings for the
presentation, please visit the GlycoMimetics website at www.glycomimetics.com.
About GlycoMimetics, Inc.
GlycoMimetics is a clinical-stage biotechnology company focused on
cancer and sickle cell disease. GlycoMimetics’ most advanced drug
candidate, rivipansel, a pan-selectin antagonist, is being developed for
the treatment of vaso-occlusive crisis in sickle cell disease and is
being evaluated in a Phase 3 clinical trial being conducted by its
strategic collaborator, Pfizer. GlycoMimetics’ wholly-owned drug
candidate, GMI-1271, an E-selectin antagonist, is being evaluated in an
ongoing Phase 1/2 clinical trial as a potential treatment for AML and in
a Phase 1 clinical trial in multiple myeloma. GlycoMimetics has also
recently initiated a clinical trial with a third drug candidate,
GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is
located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com